Reaffirms FY25 Revenue View at $3.91M-$3.94M
Reaffirms FY25 revenue view $3.91M-$3.94M, up 20% y/y.
Trade with 70% Backtested Accuracy
Analyst Views on TNON
About TNON
About the author
Tenon Medical Announces 2025 Financial Results Release Date
- Quarterly Revenue Growth: Fourth quarter 2025 revenue is projected to be between $1.45 million and $1.48 million, representing approximately 90% year-over-year growth, indicating strong market performance and sustained growth potential for the company.
- Annual Revenue Performance: Full year 2025 revenue is expected to range from $3.91 million to $3.94 million, reflecting a year-over-year growth of about 20%, showcasing Tenon Medical's robust development and increasing market demand in the medical device sector.
- Earnings Release Schedule: The company plans to release its financial results for the fourth quarter and full year 2025 after market close on March 19, 2026, and will hold a conference call to discuss financial details, enhancing investor communication.
- Product Innovation and Market Opportunities: Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon Medical has focused on three commercial opportunities, including primary SI joint procedures, revision of failed SI joint implants, and augmenting spinal fusion, demonstrating its strategic positioning in the medical market.
Tenon Medical (TNON) Q2 2025 Earnings Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Tenon Medical Revenue Falls 37 Percent
Financial Performance and Acquisition: Tenon Medical reported a 37.4% decline in revenue for Q2 2025, alongside a significant reduction in operating expenses. The recent acquisition of CyVantage is expected to enhance product offerings and facilitate revenue recovery.
Product Launches and Market Expansion: The company plans to launch the Catamaran SE implant this quarter and initiate alpha surgeries for Symmetry Plus by year-end, aiming to expand its market presence in sacropelvic fixation and drive sales growth through strategic integration and cross-selling opportunities.
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Astera Labs Financial Performance: Astera Labs, Inc. shares surged 17.3% in pre-market trading after reporting a record $191.9 million in revenue for Q2, a 20% increase from the previous quarter and a 150% year-over-year rise, along with optimistic third-quarter guidance.
Market Movements: Several stocks experienced significant pre-market trading fluctuations, with BiomX Inc. gaining 34.2% following a stake report by Morgan Stanley, while LifeMD, Inc. saw a decline of 28.8% due to disappointing financial results and weak guidance.
3 Penny Stocks to Watch Now, 8/5/25
Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, and I-Mab are highlighted as penny stocks to monitor on August 5, 2025, based on their significant Dollar Volume and recent stock price movements.
Company Highlights: Tenon Medical focuses on innovative solutions for SIJ disorders; BioXcel Therapeutics is advancing AI-enabled treatments with promising trial results; and I-Mab is developing immuno-oncology agents, recently securing a substantial equity offering.
Crude Oil Down 2%; Amazon Shares Tumble After Q2 Results
U.S. Stock Market Performance: U.S. stocks experienced a decline, with the Dow Jones falling 1.5%, NASDAQ down 2.38%, and S&P 500 dropping 1.76%. Notable movements included Amazon's shares plummeting 8% after disappointing financial results, while Tenon Medical and Performant Healthcare saw significant gains.
Global Market Trends: European and Asian markets also closed lower, reflecting a broader trend of declining equities. Economic indicators showed a decrease in U.S. construction spending and a drop in manufacturing PMI, suggesting potential economic slowdown.
Tenon Medical Announces 2025 Financial Results Release Date
- Quarterly Revenue Growth: Fourth quarter 2025 revenue is projected to be between $1.45 million and $1.48 million, representing approximately 90% year-over-year growth, indicating strong market performance and sustained growth potential for the company.
- Annual Revenue Performance: Full year 2025 revenue is expected to range from $3.91 million to $3.94 million, reflecting a year-over-year growth of about 20%, showcasing Tenon Medical's robust development and increasing market demand in the medical device sector.
- Earnings Release Schedule: The company plans to release its financial results for the fourth quarter and full year 2025 after market close on March 19, 2026, and will hold a conference call to discuss financial details, enhancing investor communication.
- Product Innovation and Market Opportunities: Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon Medical has focused on three commercial opportunities, including primary SI joint procedures, revision of failed SI joint implants, and augmenting spinal fusion, demonstrating its strategic positioning in the medical market.
Tenon Medical (TNON) Q2 2025 Earnings Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Tenon Medical Revenue Falls 37 Percent
Financial Performance and Acquisition: Tenon Medical reported a 37.4% decline in revenue for Q2 2025, alongside a significant reduction in operating expenses. The recent acquisition of CyVantage is expected to enhance product offerings and facilitate revenue recovery.
Product Launches and Market Expansion: The company plans to launch the Catamaran SE implant this quarter and initiate alpha surgeries for Symmetry Plus by year-end, aiming to expand its market presence in sacropelvic fixation and drive sales growth through strategic integration and cross-selling opportunities.
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Astera Labs Financial Performance: Astera Labs, Inc. shares surged 17.3% in pre-market trading after reporting a record $191.9 million in revenue for Q2, a 20% increase from the previous quarter and a 150% year-over-year rise, along with optimistic third-quarter guidance.
Market Movements: Several stocks experienced significant pre-market trading fluctuations, with BiomX Inc. gaining 34.2% following a stake report by Morgan Stanley, while LifeMD, Inc. saw a decline of 28.8% due to disappointing financial results and weak guidance.
3 Penny Stocks to Watch Now, 8/5/25
Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, and I-Mab are highlighted as penny stocks to monitor on August 5, 2025, based on their significant Dollar Volume and recent stock price movements.
Company Highlights: Tenon Medical focuses on innovative solutions for SIJ disorders; BioXcel Therapeutics is advancing AI-enabled treatments with promising trial results; and I-Mab is developing immuno-oncology agents, recently securing a substantial equity offering.
Crude Oil Down 2%; Amazon Shares Tumble After Q2 Results
U.S. Stock Market Performance: U.S. stocks experienced a decline, with the Dow Jones falling 1.5%, NASDAQ down 2.38%, and S&P 500 dropping 1.76%. Notable movements included Amazon's shares plummeting 8% after disappointing financial results, while Tenon Medical and Performant Healthcare saw significant gains.
Global Market Trends: European and Asian markets also closed lower, reflecting a broader trend of declining equities. Economic indicators showed a decrease in U.S. construction spending and a drop in manufacturing PMI, suggesting potential economic slowdown.
